From USFDA
Cadila Healthcare announced that Zydus has received final approval from the USFDA for Glyburide Tablets USP in strengths 1.25, 2.5 and 5 mg. Glyburide, which is an anti diabetic drug will be produced at the group's formulations manufacturing facility at Baddi.Powered by Capital Market - Live News
